dc.contributor.author | Taşdemir, Mehmet | |
dc.contributor.author | Canpolat, Nur | |
dc.contributor.author | Yıldız, Nurdan | |
dc.contributor.author | Özçelik, Gül | |
dc.contributor.author | Benzer, Meryem | |
dc.contributor.author | Saygılı, Seha Kamil | |
dc.contributor.author | Özkayın, Emine Neşe | |
dc.contributor.author | Türkkan, Özde Nisa | |
dc.contributor.author | Balat, Ayşe | |
dc.contributor.author | Candan, Cengiz | |
dc.contributor.author | Çelakıl, Mehtap | |
dc.contributor.author | Yavuz, Sevgi | |
dc.contributor.author | Akıncı, Nurver | |
dc.contributor.author | Göknar, Nilüfer | |
dc.contributor.author | Akgün, Cihangir | |
dc.contributor.author | Tülpar, Sebahat | |
dc.contributor.author | Alpay, Harika | |
dc.contributor.author | Sever, Fatma Lale | |
dc.contributor.author | Bilge, İlmay | |
dc.date.accessioned | 2021-09-09T09:25:52Z | |
dc.date.available | 2021-09-09T09:25:52Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Taşdemir, M., Canpolat, N., Yıldız, N., Özçelik, G., Benzer, M., Saygılı, S. K. ... Bilge, İ. (2021). Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study. Turkish Journal of Medical Sciences, 51(4), 1781-1790. https://dx.doi.org/10.3906/sag-2012-297 | en_US |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issn | 1303-6165 | |
dc.identifier.uri | https://dx.doi.org/10.3906/sag-2012-297 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/8066 | |
dc.description.abstract | Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen.
Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared.
Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups.
Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | TÜBİTAK Scientific and Technological Research Council of Turkey | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Frequently Relapsing Nephrotic Syndrome | en_US |
dc.subject | Immunosuppressive Agents | en_US |
dc.subject | Steroid-Dependent Nephrotic Syndrome | en_US |
dc.subject | Steroid-Resistant Nephrotic Syndrome | en_US |
dc.subject | Remission | en_US |
dc.title | Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Turkish Journal of Medical Sciences | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-6026-1064 | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1781 | en_US |
dc.identifier.endpage | 1790 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3906/sag-2012-297 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.trdizinid | 480445 | en_US |
dc.identifier.scopusquality | Q3 | en_US |